{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T22:43:16Z","timestamp":1773441796150,"version":"3.50.1"},"reference-count":76,"publisher":"Bentham Science Publishers Ltd.","issue":"15","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy has emerged as\na revolutionary approach for cancer treatment, especially for hematologic cancers. However,\nCAR-T therapy has some limitations, including cytokine release syndrome (CRS), immune cellassociated\nneurologic syndrome (ICANS), and difficulty in targeting solid tumors and delivering\nallogeneic cell therapy due to graft-versus-host disease (GvHD). Therefore, it is important to\nexplore other cell sources for CAR engineering. Invariant natural killer T (iNKT) cells are a\npotential target, as they possess powerful antitumor ability and do not recognize mismatched\nmajor histocompatibility complexes (MHCs) and protein antigens, thus avoiding the risk of\nGvHD. CAR-engineered iNKT (CAR-iNKT) cell therapy offers a promising new approach to\ncancer immunotherapy by overcoming the drawbacks of CAR-T cell therapy while retaining\npotent antitumor capabilities. This review summarizes the current CAR-iNKT cell products,\ntheir functions and phenotypes, and their potential for off-the-shelf cancer immunotherapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113892010265228231116073012","type":"journal-article","created":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T10:48:07Z","timestamp":1707043687000},"page":"2001-2011","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Harnessing Chimeric Antigen Receptor-engineered Invariant Natural\nKiller T Cells: Therapeutic Strategies for Cancer and the Tumor\nMicroenvironment"],"prefix":"10.2174","volume":"25","author":[{"given":"Yiqing","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Chemistry, Biochemistry, University of Washington, Seattle, WA 98105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ruide","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","volume":"2","author":"Labanieh L.","year":"2018","unstructured":"Labanieh L.; Majzner R.G.; Mackall C.L.; Programming CAR-T cells to kill cancer. Nat Biomed Eng  2018,2(6),377-391","journal-title":"Nat Biomed Eng"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.3390\/ijms20112839","volume":"20","author":"Rotolo R.","year":"2019","unstructured":"Rotolo R.; Leuci V.; Donini C.; Cykowska A.; Gammaitoni L.; Medico G.; Valabrega G.; Aglietta M.; Sangiolo D.; CAR-based strategies beyond T lymphocytes: Integrative opportunities for cancer adoptive immunotherapy. Int J Mol Sci  2019,20(11),2839","journal-title":"Int J Mol Sci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/ejh.13170","volume":"101","author":"Kriegsmann K.","year":"2018","unstructured":"Kriegsmann K.; Kriegsmann M.; von Bergwelt-Baildon M.; Cremer M.; Witzens-Harig M.; NKT cells-New players in CAR cell immunotherapy? Eur J Haematol  2018,101(6),750-757","journal-title":"Eur J Haematol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fimmu.2018.00384","volume":"9","author":"Wolf B.J.","year":"2018","unstructured":"Wolf B.J.; Choi J.E.; Exley M.A.; Novel approaches to exploiting invariant NKT cells in cancer immunotherapy. Front Immunol  2018,9,384","journal-title":"Front Immunol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.3389\/fimmu.2018.01838","volume":"9","author":"Terabe M.","year":"2018","unstructured":"Terabe M.; Berzofsky J.A.; Tissue-specific roles of NKT cells in tumor immunity. Front Immunol  2018,9,1838","journal-title":"Front Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"9520","DOI":"10.3390\/ijms22179520","volume":"22","author":"Zarobkiewicz M.K.","year":"2021","unstructured":"Zarobkiewicz M.K.; Morawska I.; Michalski A.; Roli\u0144ski J.; Bojarska-Junak A.; NKT and NKT-like cells in autoimmune neuroinflammatory diseases\u2014Multiple Sclerosis, Myasthenia Gravis and Guillain-Barre Syndrome. Int J Mol Sci  2021,22(17),9520","journal-title":"Int J Mol Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1348-0421.2011.00338.x","volume":"55","author":"Kinjo Y.","year":"2011","unstructured":"Kinjo Y.; Ueno K.; iNKT cells in microbial immunity: Recognition of microbial glycolipids. Microbiol Immunol  2011,55(7),472-482","journal-title":"Microbiol Immunol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"897750","DOI":"10.3389\/fmed.2022.897750","volume":"9","author":"Delfanti G.","year":"2022","unstructured":"Delfanti G.; Dellabona P.; Casorati G.; Fedeli M.; Adoptive immunotherapy with engineered inkt cells to target cancer cells and the suppressive microenvironment. Front Med  2022,9,897750","journal-title":"Front Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12272-019-01139-8","volume":"42","author":"Bae E.A.","year":"2019","unstructured":"Bae E.A.; Seo H.; Kim I.K.; Jeon I.; Kang C.Y.; Roles of NKT cells in cancer immunotherapy. Arch Pharm Res  2019,42(7),543-548","journal-title":"Arch Pharm Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clim.2011.01.009","volume":"140","author":"Motohashi S.","year":"2011","unstructured":"Motohashi S.; Okamoto Y.; Yoshino I.; Nakayama T.; Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol  2011,140(2),167-176","journal-title":"Clin Immunol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"101342","DOI":"10.1016\/j.tranon.2022.101342","volume":"17","author":"Liu Y.","year":"2022","unstructured":"Liu Y.; Wang G.; Chai D.; Dang Y.; Zheng J.; Li H.; iNKT: A new avenue for CAR-based cancer immunotherapy. Transl Oncol  2022,17,101342","journal-title":"Transl Oncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.ymthe.2017.03.034","volume":"25","author":"Rivi\u00e8re I.","year":"2017","unstructured":"Rivi\u00e8re I.; Sadelain M.; Chimeric antigen receptors: A cell and gene therapy perspective. Mol Ther  2017,25(5),1117-1124","journal-title":"Mol Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.trsl.2017.06.003","volume":"187","author":"Bollino D.","year":"2017","unstructured":"Bollino D.; Webb T.J.; Chimeric antigen receptor\u2013engineered natural killer and natural killer T cells for cancer immunotherapy. Transl Res  2017,187,32-43","journal-title":"Transl Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"Sadelain M.","year":"2013","unstructured":"Sadelain M.; Brentjens R.; Rivi\u00e8re I.; The basic principles of chimeric antigen receptor design. Cancer Discov  2013,3(4),388-398","journal-title":"Cancer Discov"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.03.012","volume":"178","author":"Jaspers J.E.","year":"2017","unstructured":"Jaspers J.E.; Brentjens R.J.; Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacol Ther  2017,178,83-91","journal-title":"Pharmacol Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1172\/JCI80010","volume":"125","author":"Sadelain M.","year":"2015","unstructured":"Sadelain M.; CAR therapy: the CD19 paradigm. J Clin Invest  2015,125(9),3392-3400","journal-title":"J Clin Invest"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1084\/jem.20011786","volume":"195","author":"Gumperz J.E.","year":"2002","unstructured":"Gumperz J.E.; Miyake S.; Yamamura T.; Brenner M.B.; Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med  2002,195(5),625-636","journal-title":"J Exp Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","volume":"34","author":"Rotolo A.","year":"2018","unstructured":"Rotolo A.; Caputo V.S.; Holubova M.; Baxan N.; Dubois O.; Chaudhry M.S.; Xiao X.; Goudevenou K.; Pitcher D.S.; Petevi K.; Kachramanoglou C.; Iles S.; Naresh K.; Maher J.; Karadimitris A.; Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting. Cancer Cell  2018,34(4),596-610.e11","journal-title":"Cancer Cell"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1600-065X.2012.01140.x","volume":"248","author":"Sallusto F.","year":"2012","unstructured":"Sallusto F.; Impellizzieri D.; Basso C.; Laroni A.; Uccelli A.; Lanzavecchia A.; Engelhardt B.; T\u2010cell trafficking in the central nervous system. Immunol Rev  2012,248(1),216-227","journal-title":"Immunol Rev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1471-4906(02)02323-2","volume":"23","author":"Kim C.","year":"2002","unstructured":"Kim C.; Butcher E.; Johnston B.; Distinct subsets of human V\u03b124-invariant NKT cells: cytokine responses and chemokine receptor expression. Trends Immunol  2002,23(11),516-519","journal-title":"Trends Immunol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1172\/JCI83476","volume":"126","author":"Tian G.","year":"2016","unstructured":"Tian G.; Courtney A.N.; Jena B.; Heczey A.; Liu D.; Marinova E.; Guo L.; Xu X.; Torikai H.; Mo Q.; Dotti G.; Cooper L.J.; Metelitsa L.S.; CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest  2016,126(6),2341-2355","journal-title":"J Clin Invest"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1158\/1078-0432.CCR-21-1329","volume":"27","author":"Simonetta F.","year":"2021","unstructured":"Simonetta F.; Lohmeyer J.K.; Hirai T.; Maas-Bauer K.; Alvarez M.; Wenokur A.S.; Baker J.; Aalipour A.; Ji X.; Haile S.; Mackall C.L.; Negrin R.S.; Allogeneic CAR invariant natural killer T cells exert potent antitumor effects through host CD8 T-cell cross-priming. Clin Cancer Res  2021,27(21),6054-6064","journal-title":"Clin Cancer Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1038\/s41467-020-19833-3","volume":"11","author":"Kuhn N.F.","year":"2020","unstructured":"Kuhn N.F.; Lopez A.V.; Li X.; Cai W.; Daniyan A.F.; Brentjens R.J.; CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function. Nat Commun  2020,11(1),6171","journal-title":"Nat Commun"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","volume":"25","author":"Drent E.","year":"2019","unstructured":"Drent E.; Poels R.; Ruiter R.; van de Donk N.W.C.J.; Zweegman S.; Yuan H.; de Bruijn J.; Sadelain M.; Lokhorst H.M.; Groen R.W.J.; Mutis T.; Themeli M.; Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor\u2013engineered T cells. Clin Cancer Res  2019,25(13),4014-4025","journal-title":"Clin Cancer Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00262-016-1803-z","volume":"65","author":"Kared H.","year":"2016","unstructured":"Kared H.; Martelli S.; Ng T.P.; Pender S.L.F.; Larbi A.; CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother  2016,65(4),441-452","journal-title":"Cancer Immunol Immunother"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/ijms22031096","volume":"22","author":"Poels R.","year":"2021","unstructured":"Poels R.; Drent E.; Lameris R.; Katsarou A.; Themeli M.; van der Vliet H.J.; de Gruijl T.D.; van de Donk N.W.C.J.; Mutis T.; Preclinical evaluation of invariant natural killer T Cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma. Int J Mol Sci  2021,22(3),1096","journal-title":"Int J Mol Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3324\/haematol.2015.137620","volume":"101","author":"Drent E.","year":"2016","unstructured":"Drent E.; Groen R.W.J.; Noort W.A.; Themeli M.; Lammerts van Bueren J.J.; Parren P.W.H.I.; Kuball J.; Sebestyen Z.; Yuan H.; de Bruijn J.; van de Donk N.W.C.J.; Martens A.C.M.; Lokhorst H.M.; Mutis T.; Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica  2016,101(5),616-625","journal-title":"Haematologica"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"Sterner R.C.","year":"2021","unstructured":"Sterner R.C.; Sterner R.M.; CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J  2021,11(4),69","journal-title":"Blood Cancer J"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1084\/jem.20031462","volume":"199","author":"Metelitsa L.S.","year":"2004","unstructured":"Metelitsa L.S.; Wu H.W.; Wang H.; Yang Y.; Warsi Z.; Asgharzadeh S.; Groshen S.; Wilson S.B.; Seeger R.C.; Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med  2004,199(9),1213-1221","journal-title":"J Exp Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","volume":"124","author":"Heczey A.","year":"2014","unstructured":"Heczey A.; Liu D.; Tian G.; Courtney A.N.; Wei J.; Marinova E.; Gao X.; Guo L.; Yvon E.; Hicks J.; Liu H.; Dotti G.; Metelitsa L.S.; Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood  2014,124(18),2824-2833","journal-title":"Blood"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","volume":"25","author":"Xu X.","year":"2019","unstructured":"Xu X.; Huang W.; Heczey A.; Liu D.; Guo L.; Wood M.; Jin J.; Courtney A.N.; Liu B.; Di Pierro E.J.; Hicks J.; Barragan G.A.; Ngai H.; Chen Y.; Savoldo B.; Dotti G.; Metelitsa L.S.; NKT cells coexpressing a GD2-specific chimeric antigen receptor and il15 show enhanced in vivo persistence and antitumor activity against neuroblastoma. Clin Cancer Res  2019,25(23),7126-7138","journal-title":"Clin Cancer Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","volume":"29","author":"Heczey A.","year":"2023","unstructured":"Heczey A.; Xu X.; Courtney A.N.; Tian G.; Barragan G.A.; Guo L.; Amador C.M.; Ghatwai N.; Rathi P.; Wood M.S.; Li Y.; Zhang C.; Demberg T.; Di Pierro E.J.; Sher A.C.; Zhang H.; Mehta B.; Thakkar S.G.; Grilley B.; Wang T.; Weiss B.D.; Montalbano A.; Subramaniam M.; Xu C.; Sachar C.; Wells D.K.; Dotti G.; Metelitsa L.S.; Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med  2023,29(6),1379-1388","journal-title":"Nat Med"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1126\/science.aax0194","volume":"367","author":"Hwang SS","year":"1979","unstructured":"Hwang SS; Lim J; Yu Z; Kong P; Sefik E; Xu H; Harman CCD; Kim LK; Lee GR; Li HB; Flavell, RA mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence. Science  2020 Mar 131979,367(6483),1255-1260","journal-title":"Science"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/tjh.galenos.2019.2019.0157","volume":"37","author":"Alada\u011f E.","year":"2020","unstructured":"Alada\u011f E.; Kelkitli E.; G\u00f6ker H.; Acute graft-versus-host disease: A brief review. Turk J Haematol  2020,37(1),1-4","journal-title":"Turk J Haematol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"593863","DOI":"10.3389\/fimmu.2020.593863","volume":"11","author":"Mammadli M.","year":"2020","unstructured":"Mammadli M.; Huang W.; Harris R.; Sultana A.; Cheng Y.; Tong W.; Pu J.; Gentile T.; Dsouza S.; Yang Q.; Bah A.; August A.; Karimi M.; Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT. Front Immunol  2020,11,593863","journal-title":"Front Immunol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"100449","DOI":"10.1016\/j.xcrm.2021.100449","volume":"2","author":"Li Y.R.","year":"2021","unstructured":"Li Y.R.; Zhou Y.; Kim Y.J.; Zhu Y.; Ma F.; Yu J.; Wang Y.C.; Chen X.; Li Z.; Zeng S.; Wang X.; Lee D.; Ku J.; Tsao T.; Hardoy C.; Huang J.; Cheng D.; Montel-Hagen A.; Seet C.S.; Crooks G.M.; Larson S.M.; Sasine J.P.; Wang X.; Pellegrini M.; Ribas A.; Kohn D.B.; Witte O.; Wang P.; Yang L.; Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep Med  2021,2(11),100449","journal-title":"Cell Rep Med"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.stem.2019.08.004","volume":"25","author":"Zhu Y.","year":"2019","unstructured":"Zhu Y.; Smith D.J.; Zhou Y.; Li Y.R.; Yu J.; Lee D.; Wang Y.C.; Di Biase S.; Wang X.; Hardoy C.; Ku J.; Tsao T.; Lin L.J.; Pham A.T.; Moon H.; McLaughlin J.; Cheng D.; Hollis R.P.; Campo-Fernandez B.; Urbinati F.; Wei L.; Pang L.; Rezek V.; Berent-Maoz B.; Macabali M.H.; Gjertson D.; Wang X.; Galic Z.; Kitchen S.G.; An D.S.; Hu-Lieskovan S.; Kaplan-Lefko P.J.; De Oliveira S.N.; Seet C.S.; Larson S.M.; Forman S.J.; Heath J.R.; Zack J.A.; Crooks G.M.; Radu C.G.; Ribas A.; Kohn D.B.; Witte O.N.; Yang L.; Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer. Cell Stem Cell  2019,25(4),542-557.e9","journal-title":"Cell Stem Cell"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"104859","DOI":"10.1016\/j.isci.2022.104859","volume":"25","author":"Li Y.R.","year":"2022","unstructured":"Li Y.R.; Zeng S.; Dunn Z.S.; Zhou Y.; Li Z.; Yu J.; Wang Y.C.; Ku J.; Cook N.; Kramer A.; Yang L.; Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. iScience  2022,25(9),104859","journal-title":"iScience"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/HS9.0000000000000220","volume":"3","author":"Karadimitris A.","year":"2019","unstructured":"Karadimitris A.; Ripoll-Fiol C.; Guerra J.C.; Invariant NKT cells as a platform for CAR immunotherapy and prevention of acute Graft-versus-Host Disease. HemaSphere  2019,3(Suppl.),31-34","journal-title":"HemaSphere"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1101\/gad.169029.111","volume":"25","author":"Shiao S.L.","year":"2011","unstructured":"Shiao S.L.; Ganesan A.P.; Rugo H.S.; Coussens L.M.; Immune microenvironments in solid tumors: new targets for therapy. Genes Dev  2011,25(24),2559-2572","journal-title":"Genes Dev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1172\/JCI37869","volume":"119","author":"Song L.","year":"2009","unstructured":"Song L.; Asgharzadeh S.; Salo J.; Engell K.; Wu H.; Sposto R.; Ara T.; Silverman A.M.; DeClerck Y.A.; Seeger R.C.; Metelitsa L.S.; V\u03b124-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest  2009,119(6),1524-1536","journal-title":"J Clin Invest"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Lin Y.","year":"2019","unstructured":"Lin Y.; Xu J.; Lan H.; Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol  2019,12(1),76","journal-title":"J Hematol Oncol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"Gordon S.R.","year":"2017","unstructured":"Gordon S.R.; Maute R.L.; Dulken B.W.; Hutter G.; George B.M.; McCracken M.N.; Gupta R.; Tsai J.M.; Sinha R.; Corey D.; Ring A.M.; Connolly A.J.; Weissman I.L.; PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature  2017,545(7655),495-499","journal-title":"Nature"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fonc.2020.00188","volume":"10","author":"Zhou J.","year":"2020","unstructured":"Zhou J.; Tang Z.; Gao S.; Li C.; Feng Y.; Zhou X.; Tumor-associated macrophages: Recent insights and therapies. Front Oncol  2020,10,188","journal-title":"Front Oncol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clim.2010.10.005","volume":"140","author":"Metelitsa L.S.","year":"2011","unstructured":"Metelitsa L.S.; Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol  2011,140(2),119-129","journal-title":"Clin Immunol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"999549","DOI":"10.3389\/fimmu.2022.999549","volume":"13","author":"Li Y.R.","year":"2022","unstructured":"Li Y.R.; Wilson M.; Yang L.; Target tumor microenvironment by innate T cells. Front Immunol  2022,13,999549","journal-title":"Front Immunol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.celrep.2018.02.058","volume":"22","author":"Cortesi F.","year":"2018","unstructured":"Cortesi F.; Delfanti G.; Grilli A.; Calcinotto A.; Gorini F.; Pucci F.; Lucian\u00f2 R.; Grioni M.; Recchia A.; Benigni F.; Briganti A.; Salonia A.; De Palma M.; Bicciato S.; Doglioni C.; Bellone M.; Casorati G.; Dellabona P.; Bimodal CD40\/Fas-dependent crosstalk between iNKT cells and tumor-associated macrophages impairs prostate cancer progression. Cell Rep  2018,22(11),3006-3020","journal-title":"Cell Rep"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.3390\/cancers14112749","volume":"14","author":"Li Y.R.","year":"2022","unstructured":"Li Y.R.; Brown J.; Yu Y.; Lee D.; Zhou K.; Dunn Z.S.; Hon R.; Wilson M.; Kramer A.; Zhu Y.; Fang Y.; Yang L.; Targeting immunosuppressive tumor-associated macrophages using innate T cells for enhanced antitumor reactivity. Cancers (Basel)  2022,14(11),2749","journal-title":"Cancers (Basel)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fimmu.2018.00367","volume":"9","author":"Krijgsman D.","year":"2018","unstructured":"Krijgsman D.; Hokland M.; Kuppen P.J.K.; The role of natural killer T cells in cancer-A phenotypical and functional approach. Front Immunol  2018,9,367","journal-title":"Front Immunol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","volume":"25","author":"Bendelac A.","year":"2007","unstructured":"Bendelac A.; Savage P.B.; Teyton L.; The biology of NKT cells. Annu Rev Immunol  2007,25(1),297-336","journal-title":"Annu Rev Immunol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/82698","volume":"1","author":"Smyth M.J.","year":"2000","unstructured":"Smyth M.J.; Godfrey D.I.; NKT cells and tumor immunity-A double-edged sword. Nat Immunol  2000,1(6),459-460","journal-title":"Nat Immunol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"eabj8760","DOI":"10.1126\/sciimmunol.abj8760","volume":"7","author":"Cui G.","year":"2022","unstructured":"Cui G.; Shimba A.; Jin J.; Ogawa T.; Muramoto Y.; Miyachi H.; Abe S.; Asahi T.; Tani-ichi S.; Dijkstra J.M.; Iwamoto Y.; Kryukov K.; Zhu Y.; Takami D.; Hara T.; Kitano S.; Xu Y.; Morita H.; Zhang M.; Zreka L.; Miyata K.; Kanaya T.; Okumura S.; Ito T.; Hatano E.; Takahashi Y.; Watarai H.; Oike Y.; Imanishi T.; Ohno H.; Ohteki T.; Minato N.; Kubo M.; Holl\u00e4nder G.A.; Ueno H.; Noda T.; Shiroguchi K.; Ikuta K.; A circulating subset of iNKT cells mediates antitumor and antiviral immunity. Sci Immunol  2022,7(76),eabj8760","journal-title":"Sci Immunol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/imr.12938","volume":"299","author":"Leadbetter E.A.","year":"2021","unstructured":"Leadbetter E.A.; Karlsson M.C.I.; Invariant natural killer T cells balance B cell immunity. Immunol Rev  2021,299(1),93-107","journal-title":"Immunol Rev"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"Maher J.","year":"2002","unstructured":"Maher J.; Brentjens R.J.; Gunset G.; Rivi\u00e8re I.; Sadelain M.; Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6\/CD28 receptor. Nat Biotechnol  2002,20(1),70-75","journal-title":"Nat Biotechnol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.leu.2403302","volume":"18","author":"Imai C.","year":"2004","unstructured":"Imai C.; Mihara K.; Andreansky M.; Nicholson I.C.; Pui C-H.; Geiger T.L.; Campana D.; Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia  2004,18(4),676-684","journal-title":"Leukemia"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.3389\/fimmu.2018.02593","volume":"9","author":"Schmidts A.","year":"2018","unstructured":"Schmidts A.; Maus M.V.; Making CAR T cells a solid option for solid tumors. Front Immunol  2018,9,2593","journal-title":"Front Immunol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"Yeku O.O.","year":"2017","unstructured":"Yeku O.O.; Purdon T.J.; Koneru M.; Spriggs D.; Brentjens R.J.; Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep  2017,7(1),10541","journal-title":"Sci Rep"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1172\/JCI36264","volume":"118","author":"De Santo C.","year":"2008","unstructured":"De Santo C.; Salio M.; Masri S.H.; Lee L.Y.H.; Dong T.; Speak A.O.; Porubsky S.; Booth S.; Veerapen N.; Besra G.S.; Gr\u00f6ne H.J.; Platt F.M.; Zambon M.; Cerundolo V.; Invariant NKT cells reduce the immunosuppressive activity of influenza A virus\u2013induced myeloid-derived suppressor cells in mice and humans. J Clin Invest  2008,118(12),4036-4048","journal-title":"J Clin Invest"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1182\/blood-2015-08-664250","volume":"127","author":"Jacoby E.","year":"2016","unstructured":"Jacoby E.; Yang Y.; Qin H.; Chien C.D.; Kochenderfer J.N.; Fry T.J.; Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood  2016,127(10),1361-1370","journal-title":"Blood"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.4049\/jimmunol.178.10.6242","volume":"178","author":"Pillai A.B.","year":"2007","unstructured":"Pillai A.B.; George T.I.; Dutt S.; Teo P.; Strober S.; Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol  2007,178(10),6242-6251","journal-title":"J Immunol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"Brudno J.N.","year":"2019","unstructured":"Brudno J.N.; Kochenderfer J.N.; Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev  2019,34,45-55","journal-title":"Blood Rev"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.3390\/ijms19082365","volume":"19","author":"Simon B.","year":"2018","unstructured":"Simon B.; Wiesinger M.; M\u00e4rz J.; Wistuba-Hamprecht K.; Weide B.; Schuler-Thurner B.; Schuler G.; D\u00f6rrie J.; Uslu U.; The generation of CAR-Transfected natural killer T cells for the immunotherapy of melanoma. Int J Mol Sci  2018,19(8),2365","journal-title":"Int J Mol Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","volume":"16","author":"Shah N.N.","year":"2019","unstructured":"Shah N.N.; Fry T.J.; Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol  2019,16(6),372-385","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1073\/pnas.1424877112","volume":"112","author":"Smith D.J.","year":"2015","unstructured":"Smith D.J.; Liu S.; Ji S.; Li B.; McLaughlin J.; Cheng D.; Witte O.N.; Yang L.; Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells. Proc Natl Acad Sci USA  2015,112(5),1523-1528","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=65","first-page":"4","year":"2013","unstructured":"Fujii S ichiro, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, Taniguchi M. NKT cells as an ideal anti-tumor immunotherapeutic. Front Immunol  2013,4","journal-title":"Front Immunol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.3910","volume":"21","author":"Rapoport A.P.","year":"2015","unstructured":"Rapoport A.P.; Stadtmauer E.A.; Binder-Scholl G.K.; Goloubeva O.; Vogl D.T.; Lacey S.F.; Badros A.Z.; Garfall A.; Weiss B.; Finklestein J.; Kulikovskaya I.; Sinha S.K.; Kronsberg S.; Gupta M.; Bond S.; Melchiori L.; Brewer J.E.; Bennett A.D.; Gerry A.B.; Pumphrey N.J.; Williams D.; Tayton- Martin, H.K.; Ribeiro, L.; Holdich, T.; Yanovich, S.; Hardy, N.; Yared, J.; Kerr, N.; Philip, S.; Westphal, S.; Siegel, D.L.; Levine, B.L.; Jakobsen, B.K.; Kalos, M.; June, C.H. NY-ESO-1\u2013specific TCR\u2013engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med  2015,21(8),914-921","journal-title":"Nat Med"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1182\/blood.V126.23.183.183","volume":"126","author":"Schuster S.J.","year":"2015","unstructured":"Schuster S.J.; Svoboda J.; Dwivedy Nasta S.; Porter D.L.; Chong E.A.; Landsburg D.J.; Mato A.R.; Lacey S.F.; Melenhorst J.J.; Chew A.; Hasskarl J.; Shah G.D.; Wasik M.A.; Marcucci K.T.; Zheng Z.; Levine B.L.; June C.H.; Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Blood  2015,126(23),183-183","journal-title":"Blood"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"Maude S.L.","year":"2014","unstructured":"Maude S.L.; Frey N.; Shaw P.A.; Aplenc R.; Barrett D.M.; Bunin N.J.; Chew A.; Gonzalez V.E.; Zheng Z.; Lacey S.F.; Mahnke Y.D.; Melenhorst J.J.; Rheingold S.R.; Shen A.; Teachey D.T.; Levine B.L.; June C.H.; Porter D.L.; Grupp S.A.; Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med  2014,371(16),1507-1517","journal-title":"N Engl J Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"Kochenderfer J.N.","year":"2015","unstructured":"Kochenderfer J.N.; Dudley M.E.; Kassim S.H.; Somerville R.P.T.; Carpenter R.O.; Stetler-Stevenson M.; Yang J.C.; Phan G.Q.; Hughes M.S.; Sherry R.M.; Raffeld M.; Feldman S.; Lu L.; Li Y.F.; Ngo L.T.; Goy A.; Feldman T.; Spaner D.E.; Wang M.L.; Chen C.C.; Kranick S.M.; Nath A.; Nathan D.A.N.; Morton K.E.; Toomey M.A.; Rosenberg S.A.; Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol  2015,33(6),540-549","journal-title":"J Clin Oncol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2017.04.004","volume":"187","author":"Zeltsman M.","year":"2017","unstructured":"Zeltsman M.; Dozier J.; McGee E.; Ngai D.; Adusumilli P.S.; CAR T-cell therapy for lung cancer and malignant pleural mesothelioma. Transl Res  2017,187,1-10","journal-title":"Transl Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.mt.6300104","volume":"15","author":"Park J.R.","year":"2007","unstructured":"Park J.R.; DiGiusto D.L.; Slovak M.; Wright C.; Naranjo A.; Wagner J.; Meechoovet H.B.; Bautista C.; Chang W.C.; Ostberg J.R.; Jensen M.C.; Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther  2007,15(4),825-833","journal-title":"Mol Ther"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"977","DOI":"10.4049\/jimmunol.179.2.977","volume":"179","author":"Sinha P.","year":"2007","unstructured":"Sinha P.; Clements V.K.; Bunt S.K.; Albelda S.M.; Ostrand-Rosenberg S.; Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol  2007,179(2),977-983","journal-title":"J Immunol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"Turtle C.J.","year":"2017","unstructured":"Turtle C.J.; Hay K.A.; Hanafi L.A.; Li D.; Cherian S.; Chen X.; Wood B.; Lozanski A.; Byrd J.C.; Heimfeld S.; Riddell S.R.; Maloney D.G.; Durable molecular remissions in chronic lymphocytic leukemia treated With CD19-Specific chimeric antigen receptor\u2013Modified T cells after failure of Ibrutinib. J Clin Oncol  2017,35(26),3010-3020","journal-title":"J Clin Oncol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"Park J.H.","year":"2018","unstructured":"Park J.H.; Rivi\u00e8re I.; Gonen M.; Wang X.; S\u00e9n\u00e9chal B.; Curran K.J.; Sauter C.; Wang Y.; Santomasso B.; Mead E.; Roshal M.; Maslak P.; Davila M.; Brentjens R.J.; Sadelain M.; Long-term follow-up of CD19 CAR therapy in acute lymphoblastic Leukemia. N Engl J Med  2018,378(5),449-459","journal-title":"N Engl J Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"Gust J.","year":"2017","unstructured":"Gust J.; Hay K.A.; Hanafi L.A.; Li D.; Myerson D.; Gonzalez-Cuyar L.F.; Yeung C.; Liles W.C.; Wurfel M.; Lopez J.A.; Chen J.; Chung D.; Harju-Baker S.; \u00d6zpolat T.; Fink K.R.; Riddell S.R.; Maloney D.G.; Turtle C.J.; Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with cd19 car-t cells. Cancer Discov  2017,7(12),1404-1419","journal-title":"Cancer Discov"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.17544","volume":"195","author":"Sanber K.","year":"2021","unstructured":"Sanber K.; Savani B.; Jain T.; Graft\u2010 versus \u2010host disease risk after chimeric antigen receptor T\u2010cell therapy: the diametric opposition of T cells. Br J Haematol  2021,195(5),660-668","journal-title":"Br J Haematol"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010265228231116073012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/225680\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010265228231116073012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T09:41:47Z","timestamp":1727084507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/225680\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":76,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892010265228231116073012","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-07-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}